Eun Hye Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eun Hye Cho has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Hee-Yeon Woo
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6 shared publications - Min-Jung Kwon
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
6 shared publications Min-Seung Park
6 shared publicationsHyosoon Park
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
5 shared publications- Chang-Seok Ki
GC Genome, Yongin, Korea
4 shared publications - Hyosoon Park
Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
4 shared publications
Latest Publications
- 14 July 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20  (9) , 2008-2019
Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes
- 14 July 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20  (9) , 2008-2019
Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes
- 31 January 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33  (2) , 377-385
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer
Background Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy. Methods A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status. Results ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71â33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24â10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98â59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73â20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001). Conclusions ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.
- 31 January 2026
- Published by Springer Nature in Breast Cancer
- Vol. 33  (2) , 377-385
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer
Background Circulating tumor DNA (ctDNA) has emerged as a prognostic biomarker for breast cancer, potentially offering a more comprehensive representation of tumor genetic heterogeneity. In this study, we assessed the prognostic and monitoring values of ctDNA at multiple clinical time points during diagnosis and therapy. Methods A total of 119 patients with breast cancer underwent ctDNA analysis using next-generation sequencing, targeting 47 breast cancer-related genes at three predefined time points (baseline, post-neoadjuvant chemotherapy [post-NAC], and follow-up). Disease-free survival (DFS) was analyzed based on ctDNA status. Results ctDNA was detected in 50.9% of patients at baseline, 25.0% post-NAC, and 58.3% during follow-up. ctDNA positivity was associated with worse DFS at baseline (hazard ratio [HR] 7.54, 95% CI: 1.71â33.17, P = 0.008), post-NAC (HR 3.54, 95% CI: 1.24â10.12, P = 0.018), and follow-up (HR 7.68, 95% CI: 0.98â59.97, P = 0.052). TP53 mutations were the most frequently observed, present in 37.5%, 14.8%, and 20.4% of patients at baseline, post-NAC, and follow-up, respectively. PIK3CA mutations were the second most common, detected in 11.6%, 4.5%, and 5.8% of patients, respectively. ctDNA positivity for these mutations consistently showed elevated HRs for disease progression across clinical time points (HR range, 2.73â20.49). ctDNA non-clearance was associated with the highest risk of disease progression (HR 81.09, P < 0.001) and remained the strongest independent prognostic factor in the multivariate analysis (HR 52.07, P < 0.001). Conclusions ctDNA analysis provides significant clinical utility for prognostic stratification and disease monitoring in breast cancer management.
- 19 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
A Novel Blood-Based Test for Colorectal Cancer Detection Using Cell-Free DNA Fragmentomics
INTRODUCTION: Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA). METHODS: In this prospective case-control study, 1,677 participants were enrolled: 1,267 with normal colonoscopy, 302 with CRC, and 108 with AA. Participants were randomly assigned to either a development cohort (n = 1,250) or a validation cohort (n = 427). Whole-genome sequencing of cfDNA was performed to extract fragmentomic features, including end motifs, fragment lengths, and genome-wide coverage. A diagnostic model was developed using the Residual Enrichment From Independent Normal Ensemble method, and its performance was assessed in the validation cohort. RESULTS: In the validation cohort, the sensitivities for CRC and AA were 90.4% (95% CI, 82.2â97.3) and 58.3% (95% CI, 48.1â67.6), respectively. Overall accuracy for advanced neoplasia was 84.8% (95% CI, 81.1â87.8), and specificity in individuals with normal colonoscopy was 94.7% (95% CI, 91.2â96.9). The areas under the receiver operating characteristic curve were 0.978 for CRC and 0.862 for AA. Sensitivities by CRC stage were 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV). Diagnostic performance was consistent across CRC locations (left vs right colon), age of patients with CRC (<60 vs âĽ60), and AA locations. DISCUSSION: This cfDNA-based blood test demonstrated high diagnostic accuracy for CRC and acceptable performance for AA. Its consistent performance across clinical subgroups suggests its potential as an effective noninvasive CRC screening tool.
- 19 November 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
A Novel Blood-Based Test for Colorectal Cancer Detection Using Cell-Free DNA Fragmentomics
INTRODUCTION: Fragmentomic analysis of blood-derived cell-free DNA (cfDNA) has emerged as a promising approach for cancer screening. We aimed to develop a novel cfDNA-based blood test and evaluate its diagnostic performance for colorectal cancer (CRC) and advanced adenoma (AA). METHODS: In this prospective case-control study, 1,677 participants were enrolled: 1,267 with normal colonoscopy, 302 with CRC, and 108 with AA. Participants were randomly assigned to either a development cohort (n = 1,250) or a validation cohort (n = 427). Whole-genome sequencing of cfDNA was performed to extract fragmentomic features, including end motifs, fragment lengths, and genome-wide coverage. A diagnostic model was developed using the Residual Enrichment From Independent Normal Ensemble method, and its performance was assessed in the validation cohort. RESULTS: In the validation cohort, the sensitivities for CRC and AA were 90.4% (95% CI, 82.2â97.3) and 58.3% (95% CI, 48.1â67.6), respectively. Overall accuracy for advanced neoplasia was 84.8% (95% CI, 81.1â87.8), and specificity in individuals with normal colonoscopy was 94.7% (95% CI, 91.2â96.9). The areas under the receiver operating characteristic curve were 0.978 for CRC and 0.862 for AA. Sensitivities by CRC stage were 84.2% (stage I), 85.0% (stage II), 94.4% (stage III), and 100.0% (stage IV). Diagnostic performance was consistent across CRC locations (left vs right colon), age of patients with CRC (<60 vs âĽ60), and AA locations. DISCUSSION: This cfDNA-based blood test demonstrated high diagnostic accuracy for CRC and acceptable performance for AA. Its consistent performance across clinical subgroups suggests its potential as an effective noninvasive CRC screening tool.
- 23 October 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20  (1) , 123-134
Associations of metabolic health and obesity with apolipoprotein B and low-density lipoprotein cholesterol discordance in a large Korean cohort
- 23 October 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20  (1) , 123-134
Associations of metabolic health and obesity with apolipoprotein B and low-density lipoprotein cholesterol discordance in a large Korean cohort
- Open Access
- 22 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (9) , e0331174
Genetic epidemiology of moyamoya disease and CADASIL in over 120,000 healthy Korean individuals: Insights into cerebrovascular disorders
Background: East Asia has one of the highest global stroke burdens. Genetically, moyamoya disease (MMD) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) contribute to this burden. This study investigated the allele frequencies and estimated the genetic prevalence of RNF213 and NOTCH3 variants in a large Korean population. Methods: Between July 2021 and August 2024, 129,933 individuals who underwent health checkups were included. RNF213 p.Arg4810Lys and three NOTCH3 variants, p.Arg544Cys, p.Arg640Cys, and p.Arg75Pro, were analyzed using next-generation sequencing. Allele frequencies were calculated, and genetic prevalence was estimated using the Hardy-Weinberg equilibrium. Results: The allele frequency of RNF213 p.Arg4810Lys was 1.08%, with 13 homozygotes. The estimated genetic prevalence of MMD was 1 in 47 individuals. For NOTCH3, the allele frequencies were 0.07% for p.Arg544Cys, 0.07% for p.Arg640Cys, and 0.04% for p.Arg75Pro, corresponding to an estimated genetic prevalence of CADASIL of 1 in 277 individuals. Eight individuals carried both the RNF213 and NOTCH3 variants. Conclusion: This large-scale study highlights the substantial genetic burden of RNF213 and NOTCH3 variants in Koreans, which partially contributes to the high stroke burden in East Asia. These findings emphasize the importance of population-specific genetic studies to optimize cerebrovascular disorder management in East Asia.
- 22 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (9) , e0331174
Open AccessGenetic epidemiology of moyamoya disease and CADASIL in over 120,000 healthy Korean individuals: Insights into cerebrovascular disorders
Background: East Asia has one of the highest global stroke burdens. Genetically, moyamoya disease (MMD) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) contribute to this burden. This study investigated the allele frequencies and estimated the genetic prevalence of RNF213 and NOTCH3 variants in a large Korean population. Methods: Between July 2021 and August 2024, 129,933 individuals who underwent health checkups were included. RNF213 p.Arg4810Lys and three NOTCH3 variants, p.Arg544Cys, p.Arg640Cys, and p.Arg75Pro, were analyzed using next-generation sequencing. Allele frequencies were calculated, and genetic prevalence was estimated using the Hardy-Weinberg equilibrium. Results: The allele frequency of RNF213 p.Arg4810Lys was 1.08%, with 13 homozygotes. The estimated genetic prevalence of MMD was 1 in 47 individuals. For NOTCH3, the allele frequencies were 0.07% for p.Arg544Cys, 0.07% for p.Arg640Cys, and 0.04% for p.Arg75Pro, corresponding to an estimated genetic prevalence of CADASIL of 1 in 277 individuals. Eight individuals carried both the RNF213 and NOTCH3 variants. Conclusion: This large-scale study highlights the substantial genetic burden of RNF213 and NOTCH3 variants in Koreans, which partially contributes to the high stroke burden in East Asia. These findings emphasize the importance of population-specific genetic studies to optimize cerebrovascular disorder management in East Asia.
- Open Access
- 1 April 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15  (2) , 169-172
Dilated Cardiomyopathy Caused by a Novel TTN Frameshift Variant in the A-band: Case Report and Implications
Youngjin Youn, M.D., Jee Ah Kim, M.D., Min-Seung Park, M.D., Min-Jung Kwon, M.D., Hee-Yeon Woo, M.D., Hyosoon Park, M.D., Eun Hye Cho, M.D.. Lab Med Online 2025;15:169-72. https://doi.org/10.47429/lmo.2025.15.2.169
- 1 April 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15  (2) , 169-172
Open AccessDilated Cardiomyopathy Caused by a Novel TTN Frameshift Variant in the A-band: Case Report and Implications
Youngjin Youn, M.D., Jee Ah Kim, M.D., Min-Seung Park, M.D., Min-Jung Kwon, M.D., Hee-Yeon Woo, M.D., Hyosoon Park, M.D., Eun Hye Cho, M.D.. Lab Med Online 2025;15:169-72. https://doi.org/10.47429/lmo.2025.15.2.169
- 21 February 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19  (3) , 477-485
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults
- 21 February 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19  (3) , 477-485
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults
- Open Access
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (2) , e0318847
Mean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease
Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain. Methods: This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (FIB-4) index: low (2.67). We evaluated the differences in MPV among these groups and analyzed the association between MPV and the FIB-4 index. Results: MPV varied significantly across the three groups categorized by the FIB-4 index (p < 0.001). Additionally, a weak but statistically significant positive correlation was observed between MPV and the FIB-4 index (rho = 0.170, p < 0.001). Multivariable linear regression adjusted for multiple covariates showed that MPV remained significantly associated with the FIB-4 index (β = 0.01, p < 0.001). Conclusions: MPV may serve as a supplementary non-invasive marker for assessing liver fibrosis in patients with NAFLD. Further studies are required to validate these findings and explore the utility of MPV in conjunction with other non-invasive markers.
- 18 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20  (2) , e0318847
Open AccessMean platelet volume as a biomarker for liver fibrosis in patients with Non-alcoholic fatty liver disease
Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent cause of chronic liver disease worldwide. Accurate assessment of liver fibrosis is essential for the prognosis and management of NAFLD. Mean platelet volume (MPV), an index of platelet activation, has been associated with liver fibrosis in various chronic liver diseases; however, its role in NAFLD remains uncertain. Methods: This study analyzed data from 70,830 patients with NAFLD who underwent a comprehensive health examination between 2015 and 2019. Patients were stratified into three groups based on the fibrosis-4 (FIB-4) index: low (2.67). We evaluated the differences in MPV among these groups and analyzed the association between MPV and the FIB-4 index. Results: MPV varied significantly across the three groups categorized by the FIB-4 index (p < 0.001). Additionally, a weak but statistically significant positive correlation was observed between MPV and the FIB-4 index (rho = 0.170, p < 0.001). Multivariable linear regression adjusted for multiple covariates showed that MPV remained significantly associated with the FIB-4 index (β = 0.01, p < 0.001). Conclusions: MPV may serve as a supplementary non-invasive marker for assessing liver fibrosis in patients with NAFLD. Further studies are required to validate these findings and explore the utility of MPV in conjunction with other non-invasive markers.
- 31 January 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32  (2) , 416-425
Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients
Background Circulating tumor DNA (ctDNA) enables non-invasive evaluation and is considered a promising tool for diagnosis, treatment selection, risk stratification, and disease monitoring. However, while the utility of ctDNA has been demonstrated in advanced-stage cancers, its detection in early breast cancer (EBC) remains limited. This study investigated the characteristics of EBC patients associated with higher ctDNA detectability. Methods A total of 101 patients with EBC were enrolled. Formalin-fixed paraffin-embedded samples (FFPEs) were obtained from biopsy tissue, and plasma samples were collected before and after neoadjuvant chemotherapy (NAC). Forty-seven breast cancer-related genes were analyzed using next-generation sequencing. The diagnostic performance of ctDNA was evaluated, and logistic regression analyses were conducted to assess the impact of clinical and molecular factors on ctDNA status. Results The most frequently identified gene was TP53 (FFPE, 66.7%; ctDNA, 46.4%), followed by PIK3CA (FFPE, 36.2%; ctDNA, 17.4%). The diagnostic performance of the three most common genes showed a sensitivity range of 11.1â58.7%, specificity of 78.3â100%, and diagnostic accuracy of 65.2â78.3%. The triple-negative breast cancer (TNBC) subtype exhibited the strongest association with ctDNA detection (odds ratio [OR] 209.50, p = 0.005) in multivariate analysis. Also, those who exhibited ctDNA clearance after NAC had a higher pathological complete response rate compared to those without clearance (38.5% vs. 11.1%, p = 0.238). Conclusions Our study highlights that ctDNA analysis can complement genetic testing from a single tissue biopsy in breast cancer patients. Furthermore, ctDNA analysis may be particularly important in patients with TNBC.
- 31 January 2025
- Published by Springer Nature in Breast Cancer
- Vol. 32  (2) , 416-425
Importance of circulating tumor DNA analysis at diagnosis in early triple-negative breast cancer patients
Background Circulating tumor DNA (ctDNA) enables non-invasive evaluation and is considered a promising tool for diagnosis, treatment selection, risk stratification, and disease monitoring. However, while the utility of ctDNA has been demonstrated in advanced-stage cancers, its detection in early breast cancer (EBC) remains limited. This study investigated the characteristics of EBC patients associated with higher ctDNA detectability. Methods A total of 101 patients with EBC were enrolled. Formalin-fixed paraffin-embedded samples (FFPEs) were obtained from biopsy tissue, and plasma samples were collected before and after neoadjuvant chemotherapy (NAC). Forty-seven breast cancer-related genes were analyzed using next-generation sequencing. The diagnostic performance of ctDNA was evaluated, and logistic regression analyses were conducted to assess the impact of clinical and molecular factors on ctDNA status. Results The most frequently identified gene was TP53 (FFPE, 66.7%; ctDNA, 46.4%), followed by PIK3CA (FFPE, 36.2%; ctDNA, 17.4%). The diagnostic performance of the three most common genes showed a sensitivity range of 11.1â58.7%, specificity of 78.3â100%, and diagnostic accuracy of 65.2â78.3%. The triple-negative breast cancer (TNBC) subtype exhibited the strongest association with ctDNA detection (odds ratio [OR] 209.50, p = 0.005) in multivariate analysis. Also, those who exhibited ctDNA clearance after NAC had a higher pathological complete response rate compared to those without clearance (38.5% vs. 11.1%, p = 0.238). Conclusions Our study highlights that ctDNA analysis can complement genetic testing from a single tissue biopsy in breast cancer patients. Furthermore, ctDNA analysis may be particularly important in patients with TNBC.
- Open Access
- 1 January 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15  (1) , 21-27
Primary Ciliary Dyskinesia: A Comprehensive Review
Eun Hye Cho, M.D.. Lab Med Online 2025;15:21-7. https://doi.org/10.47429/lmo.2025.15.1.21
- 1 January 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15  (1) , 21-27
Open AccessPrimary Ciliary Dyskinesia: A Comprehensive Review
Eun Hye Cho, M.D.. Lab Med Online 2025;15:21-7. https://doi.org/10.47429/lmo.2025.15.1.21